Drug intelligence / Profile preview

CH-30

Development stage
Unknown
Lead developer
Curanter
Administration
Oral
01

Overview

CH-30 is a homeopathic remedy developed and marketed by Curanter Homeo, a retail company based in Patna, India. The product is available in oral forms, including drops and tablets. As a homeopathic preparation, it is produced through a process of serial dilution and succussion, and the manufacturer provides no specific pharmacological mechanism of action, biological targets, or clinical trial data. It is part of a commercial product line ranging from CH-19 to CH-31 sold directly to consumers via an e-commerce platform.

Brand names
CH-30CH30CH 30
Other names
CH-30 dropsCH30 dropsCH 30 dropsCH-30 tabletsCH30 tabletsCH 30 tablets

Beyond the preview

Go deeper on CH-30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH-30.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call